AMAG Pharmaceuticals, Inc. at UBS Global Healthcare Conference (Replay)
May.18.2015 at 3:00 p.m. ET
AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products.
AMAG’s lead product, a therapeutic iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD), has received regulatory approvals in the United States, European Union, Switzerland and Canada. To learn more about our products, click here.
Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company’s commercial footprint and focus on hematology and oncology centers and hospital infusion centers.